Adalimumab, another TNF-α specific monoclonal antibody used in human patients for peripheral conditions, significantly attenuated neuroinflammation and neuronal damage while also decreasing BACE-1 expression and amyloid load in rodent models of AD [347]. This evidence concerns the gene TNF and Alzheimer disease.